Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression

Neoplasia

Volumn 14, Issue 3, 2012, Pages 190-205

  Derer, Stefanie ^a   Berger, Sven ^a   Schlaeth, Martin ^a   Schneider Merck, Tanja ^a   Klausz, Katja ^a   Lohse, Stefan ^a   Overdijk, Marije B ^b   Dechant, Michael ^a   Kellner, Christian ^a   Nagelmeier, Iris ^c,d   Scheel, Andreas H ^c   van Bueren, Jeroen J Lammerts ^b   van de Winkel, Jan G J ^b   Parren, Paul W H I ^b   Peipp, Matthias ^a   Valerius, Thomas ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b University Hospital Schleswig Holstein ^*

^c Pathologie Nordhessen   (Germany)

^d Targos Molecular Pathology GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING PROTEIN 2; ACTIVATING TRANSCRIPTION FACTOR 2; CCAAT ENHANCER BINDING PROTEIN BETA; CETUXIMAB; CORE BINDING FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FORKHEAD TRANSCRIPTION FACTOR; HYPOXIA INDUCIBLE FACTOR; IMMUNOGLOBULIN G1; STAT5 PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ZALUTUMUMAB;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CELL VIABILITY; COLORECTAL CANCER; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOTOXICITY TEST; FEMALE; FLOW CYTOMETRY; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; WESTERN BLOTTING;

EID: 84859168799     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.111636     Document Type: Article

References (62)

1. Mendelsohn J (2002). Targeting the epidermal growth factor receptor. J Clin Oncol 20, 1s-13s.
2. Pao W and Miller VA (2005). Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23, 2556-2568.
3. Ciardiello F and Tortora G (2008). EGFR antagonists in cancer treatment. N Engl J Med 358, 1160-1174.
4. Peipp M, Dechant M, and Valerius T (2008). Effector mechanisms of ErbB antibodies. Curr Opin Immunol 20, 436-443.
5. Bardelli A and Siena S (2010). Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28, 1254-1261.
6. Van Cutsem E, Kohne C-H, Hitre E, Zaluski J, Chang Chien C-R, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, et al. (2009). Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360, 1408-1417.
7. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, et al. (2009). Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27, 663-671.
8. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, et al. (2008). KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26, 374-379.
9. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et al. (2008). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26, 1626-1634.
10. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, et al. (2008). Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26, 5705-5712.
11. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, et al. (2007). Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25, 3230-3237.
12. Downward J (2006). Prelude to an anniversary for the RAS oncogene. Science 314, 433-434.
13. Schubbert S, Shannon K, and Bollag G (2007). Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7, 295-308.
14. Bos JL (1989). Ras oncogenes in human cancer: a review. Cancer Res 49, 4682-4689.
15. Lau KS and Haigis KM (2009). Non-redundancy within the RAS oncogene family: insights into mutational disparities in cancer. Mol Cells 28, 315-320.
16. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, and Schilsky RL (2009). American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27, 2091-2096.
17. de Haij S, Jansen JH, Boross P, Beurskens FJ, Bakema JE, Bos DL, Martens A, Verbeek JS, Parren PW, van de Winkel JG, et al. (2010). In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res 70, 3209-3217.
18. Zhang W, Gordon MS, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, et al. (2007). FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor-expressing metastatic coloreactal cancer patients treated with single-agent cetuximab. J Clin Oncol 25, 3712-3718.
19. Schlaeth M, Berger S, Derer S, Klausz K, Lohse S, Dechant M, Lazar GA, Schneider-Merck T, Peipp M, and Valerius T (2010). Fc-engineered EGF-Rantibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells. Cancer Sci 101, 1080-1088.
20. Dechant M, Weisner W, Berger S, Peipp M, Beyer T, Schneider-Merck T, Lammerts van Bueren JJ, Bleeker WK, Parren PW, van de Winkel JG, et al. (2008). Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res 68, 4998-5003.
21. Idusogie EE, Wong PY, Presta LG, Gazzano-Santoro H, Totpal K, Ultsch M, and Mulkerrin MG (2001). Engineered antibodies with increased activity to recruit complement. J Immunol 166, 2571-2575.
22. Schneider-Merck T, Lammerts van Bueren JJ, Berger S, Rossen K, van Berkel PH, Derer S, Beyer T, Lohse S, Bleeker WK, Peipp M, et al. (2010). Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 184, 512-520.
23. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C, and Franklin WA (2003). Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21, 3798-3807.
24. Lee HJ, Xu X, Choe G, Chung DH, Seo JW, Lee JH, Lee CT, Jheon S, Sung SW, and Chung JH (2010). Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study. Lung Cancer 68, 375-382.
25. Barnes DW (1982). Epidermal growth factor inhibits growth of A431 human epidermoid carcinoma in serum-free cell culture. J Cell Biol 93, 1-4.
26. Overdijk MB, Verploegen S, van den Brakel JH, Lammerts van Bueren JJ, Vink T, van de Winkel JG, Parren PW, and Bleeker WK (2011). Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J Immunol 187, 3383-3390.
27. Lopez-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S, and Ferris RL (2009). Role of polymorphic Fcγ receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 58, 1853-1864.
28. Shuman JD, Sebastian T, Kaldis P, Copeland TD, Zhu S, Smart RC, andJohnson PF (2004). Cell cycle-dependent phosphorylation of C/EBPβ mediates oncogenic cooperativity between C/EBPβ and H-RasV12. Mol Cell Biol 24, 7380-7391.
29. Mo X, Kowenz-Leutz E, Xu H, and Leutz A (2004). Ras induces mediator complex exchange on C/EBP β. Mol Cell 13, 241-250.
30. Gustafson TL, Wellberg E, Laffin B, Schilling L, Metz RP, Zahnow CA, and Porter WW (2009). Ha-Ras transformation of MCF10A cells leads to repression of Singleminded-2s through NOTCH and C/EBPβ. Oncogene 28, 1561-1568.
31. Atwood AA and Sealy L (2010). Regulation of C/EBPβ1 by Ras in mammary epithelial cells and the role of C/EBPβ1 in oncogene-induced senescence. Oncogene 29, 6004-6015.
32. Tsukada J, Yoshida Y, Kominato Y, and Auron PE (2011). The CCAAT/ enhancer (C/EBP) family of basic-leucine zipper (bZIP) transcription factors is a multifaceted highly-regulated system for gene regulation. Cytokine 54, 6-19.
33. Sebastian T and Johnson PF (2009). RasV12-mediated down-regulation of CCAAT/enhancer binding protein β in immortalized fibroblasts requires loss of p19Arf and facilitates bypass of oncogene-induced senescence. Cancer Res 69, 2588-2598.
34. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, et al. (2010). Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304, 1812-1820.
35. Guerrero S, Casanova I, Farre L, Mazo A, Capella G, and Mangues R (2000). K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 60, 6750-6756.
36. Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, Kondo C, Mizota A, Utsunomiya S, Muro K, et al. (2011). BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104, 856-862.
37. Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, Touge H, Makino H, Takata M, Miyata M, et al. (2007). Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 13, 1552-1561.
38. Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, Gerritsen AF, Pluyter M, Houtkamp M, Halk E, Goldstein J, Schuurman J, van Dijk MA, et al. (2004). Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 173, 4699-4707.
39. Arena S, Isella C, Martini M, de Marco A, Medico E, and Bardelli A (2007). Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers. Cancer Res 67, 8468-8476.
40. Kato K, Ueoka Y, Tamura T, Nishida J, and Wake N (1998). Oncogenic Ras modulates epidermal growth factor responsiveness in endometrial carcinomas. Eur J Cancer 34, 737-744.
41. van Houdt WJ, Hoogwater FJ, de Bruijn MT, Emmink BL, Nijkamp MW, Raats DA, van der Groep P, van Diest P, Borel Rinkes IH, and Kranenburg O (2010). Oncogenic KRAS desensitizes colorectal tumor cells to epidermal growth factor receptor inhibition and activation. Neoplasia 12, 443-452.
42. Yokota T, Bui T, Liu Y, Yi M, Hunt KK, and Keyomarsi K (2007). Differential regulation of elafin in normal and tumor-derived mammary epithelial cells is mediated by CCAAT/enhancer binding protein β. Cancer Res 67, 11272-11283.
43. Rask K, Thorn M, Ponten F, Kraaz W, Sundfeldt K, Hedin L, and Enerback S (2000). Increased expression of the transcription factors CCAAT-enhancer binding protein-β (C/EBBeta) and C/EBzeta (CHOP) correlate with invasiveness of human colorectal cancer. Int J Cancer 86, 337-343.
44. Pal R, Janz M, Galson DL, Gries M, Li S, Johrens K, Anagnostopoulos I, Dorken B, Mapara MY, Borghesi L, et al. (2009). C/EBPβ regulates transcription factors critical for proliferation and survival of multiple myeloma cells. Blood 114, 3890-3898.
45. Raught B, Gingras AC, James A, Medina D, Sonenberg N, and Rosen JM (1996). Expression of a translationally regulated, dominant-negative CCAAT/ enhancer-binding protein β isoform and up-regulation of the eukaryotic translation initiation factor 2α are correlated with neoplastic transformation of mammary epithelial cells. Cancer Res 56, 4382-4386.
46. Zahnow CA, Cardiff RD, Laucirica R, Medina D, and Rosen JM (2001). A role for CCAAT/enhancer binding protein β-liver-enriched inhibitory protein in mammary epithelial cell proliferation. Cancer Res 61, 261-269.
47. Zahnow CA, Younes P, Laucirica R, and Rosen JM (1997). Overexpression of C/EBPβ-LIP, a naturally occurring, dominant-negative transcription factor, in human breast cancer. J Natl Cancer Inst 89, 1887-1891.
48. Saint-Auret G, Danan JL, Hiron M, Blache C, Sulpice E, Tendil S, Daveau M, Gidrol X, and Salier JP (2011). Characterization of the transcriptional signature of C/EBPβ isoforms (LAP/LIP) in Hep3B cells: implication of LIP in prosurvival functions. J Hepatol 54, 1185-1194.
49. Ishii S, Xu YH, Stratton RH, Roe BA, Merlino GT, and Pastan I (1985). Characterization and sequence of the promoter region of the human epidermal growth factor receptor gene. Proc Natl Acad Sci USA 82, 4920-4924.
50. Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, Oldrini B, Tanaka K, Dang J, Kubek S, Palaskas N, et al. (2010). The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc Natl Acad Sci USA 107, 6459-6464.
51. Ray D, Ahsan A, Helman A, Chen G, Hegde A, Gurjar SR, Zhao L, Kiyokawa H, Beer DG, Lawrence TS, et al. (2011). Regulation of EGFR protein stability by the HECT-type ubiquitin ligase SMURF2. Neoplasia 13, 570-578.
52. Patel D, Guo X, Ng S, Melchior M, Balderes P, Burtrum D, Persaud K, Luna X, Ludwig DL, and Kang X (2010). IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab. Hum Antibodies 19, 89-99.
53. Paz-Ares LG, Gomez-Roca C, Delord JP, Cervantes A, Markman B, Corral J, Soria JC, Berge Y, Roda D, Russell-Yarde F, et al. (2011). Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 29, 3783-3790.
54. Hebbar M, Wacrenier A, Desauw C, Romano O, Cattan S, Triboulet JP, and Pruvot FR (2006). Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 17, 855-857.
55. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, et al. (2005). Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23, 1803-1810.
56. Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC, Dziadziuszko R, Gumerlock P, Chansky K, West H, et al. (2007). Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 18, 752-760.
57. Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G, Sobrero A, Barone C, Cascinu S, Colucci G, et al. (2007). Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 25, 3238-3245.
58. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, and Bardelli A (2005). Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6, 279-286.
59. Personeni N, Fieuws S, Piessevaux H, De Hertogh G, De Schutter J, Biesmans B, De Roock W, Capoen A, Debiec-Rychter M, Van Laethem JL, et al. (2008). Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res 14, 5869-5876.
60. Bengala C, Bettelli S, Bertolini F, Salvi S, Chiara S, Sonaglio C, Losi L, Bigiani N, Sartori G, Dealis C, et al. (2009). Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Ann Oncol 20, 469-474.
61. Yen LC, Yeh YS, Chen CW, Wang HM, Tsai HL, Lu CY, Chang YT, Chu KS, Lin SR, and Wang JY (2009). Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 15, 4508-4513.
62. Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE, Paz-Ares L, Storkel S, et al. (2012). EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 13, 33-42.